1,238.00
+19(+1.56%)
Currency In GBp
Address
10710 Midlothian Turnpike
North Chesterfield, VA 23235
United States of America
Phone
804 379 1090
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1030
First IPO Date
December 22, 2014
| Name | Title | Pay | Year Born |
| Mr. Joseph J. Ciaffoni | Chief Executive Officer & Director | 3,007 | 1971 |
| Mr. Ryan Preblick | Chief Financial Officer | 576,527 | 1976 |
| Ms. Cynthia Cetani | Chief Integrity & Compliance Officer | 0 | 1966 |
| Mr. Jeffrey W. Burris J.D. | Chief Legal Officer | 0 | 1972 |
| Mr. Hillel West | Chief Manufacturing & Supply Officer | 0 | 1968 |
| Mr. Vishal Kalia | Chief Strategy & Operating Officer | 0 | 1981 |
| Mr. Jason Thompson | Vice President of Investor Relations | 0 | N/A |
| Ms. Angela Colon-Mahoney M.S. | Chief Human Resources Officer | 0 | 1976 |
| Dr. Christian Heidbreder | Chief Scientific Officer | 0 | 1963 |
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.